NCT03847610

Brief Summary

This study is an in-house feasibility study of a microneedle biosensor developed within Imperial College London.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for phase_1 healthy-volunteers

Timeline
Completed

Started Apr 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 12, 2018

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 10, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 10, 2018

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

February 7, 2019

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 20, 2019

Completed
1.9 years until next milestone

Results Posted

Study results publicly available

December 29, 2020

Completed
Last Updated

March 27, 2024

Status Verified

March 1, 2024

Enrollment Period

4 months

First QC Date

February 7, 2019

Results QC Date

November 6, 2020

Last Update Submit

March 26, 2024

Conditions

Keywords

PharmacokineticsPenicillin VPenicillinsProof of Concept StudyClinical Trial, Phase IMicroneedle array

Outcome Measures

Primary Outcomes (1)

  • Assessment of the Biosensors Ability to Track Phenoxymethylpenicillin Concentrations Compared to Observations Made by Microdialysis and Blood Sampling

    Bland-Altman plot to describe agreement between interstitial phenoxymethylpenicillin concentrations and microneedle data (mean difference between microneedle and microdialysis measurements)

    Up to 12 hours

Study Arms (1)

Healthy volunteer

EXPERIMENTAL
Drug: Phenoxymethyl PenicillinDevice: Microneedle array

Interventions

Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study

Healthy volunteer

The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.

Healthy volunteer

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult \>18 years old
  • Healthy with no evidence of active infection
  • Previously received penicillin with no adverse effects

You may not qualify if:

  • High risk of skin soft tissue infection or local skin and soft tissue infection near sensor site
  • Previous history of allergies to adhesive strips or active dermatitis
  • Penicillin allergy or previous adverse event whilst receiving penicillin
  • Anaemia on screening bloods (defined as haemoglobin \<13 g/dL in males and \<12 g/dL in females)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NIHR Imperial CRF

London, W12 0HS, United Kingdom

Location

Related Publications (1)

  • Rawson TM, Gowers SAN, Freeman DME, Wilson RC, Sharma S, Gilchrist M, MacGowan A, Lovering A, Bayliss M, Kyriakides M, Georgiou P, Cass AEG, O'Hare D, Holmes AH. Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers. Lancet Digit Health. 2019 Nov;1(7):e335-e343. doi: 10.1016/S2589-7500(19)30131-1. Epub 2019 Sep 30.

MeSH Terms

Interventions

Penicillin V

Intervention Hierarchy (Ancestors)

Penicillinsbeta-LactamsLactamsAmidesOrganic ChemicalsSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Results Point of Contact

Title
Richard Wilson
Organization
Imperial College London

Study Officials

  • Alison H Holmes, MD MPH MBBS

    Health Protection Research Unit in HCAI & AMR

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
DEVICE FEASIBILITY
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 7, 2019

First Posted

February 20, 2019

Study Start

April 12, 2018

Primary Completion

August 10, 2018

Study Completion

August 10, 2018

Last Updated

March 27, 2024

Results First Posted

December 29, 2020

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations